Pilot and Feasibility Program

项目概要-试点和可行性方案 芝加哥糖尿病转化研究中心（CCDTR）的试点和可行性资助计划 支持糖尿病相关翻译研究的新领域，特别关注弱势群体 人口。P&F计划的主要目的是为研究人员提供资金，以探索新的假设 并获得初步数据，以确保传统供资机制的长期支持。 来自P&F计划的资金支持了寻求完全独立的新调查人员 糖尿病转化研究的科学家和寻求启动糖尿病的既定研究人员- 相关研究。自2011年成立以来，CCDTR P&F计划已收到20份申请， 获得11笔赠款。到目前为止，这些试点赠款已导致15个摘要介绍，4个同行评审 出版物，并提交了10份赠款申请，随后获得了NIDDK，NHBLI， AHRQ。P&F计划为许多调查人员带来了改变，并启动了以下人员的职业生涯： 糖尿病转化研究领域的几位研究人员。我们的资金范围体现在 获得资助的机构数量和干预措施类型。大约40%的赠款获得者来自非政府组织， 芝加哥大学。受赠者的研究领域包括睡眠干预评估， 改善糖尿病结局，改善终末期肾病患者的护理，社区卫生 工人干预、移动的电话干预对久坐行为的影响以及2型糖尿病女性的结局 糖尿病和乳腺癌展望未来，我们计划继续我们成功的P&F计划， 在促进合作方面是CCDTR不可或缺的一部分，并导致了重要的研究成果， 进一步扩大其范围。我们要求继续提供每年50 000美元的支助。院长 生物科学部，医学博士Kenneth Polonsky将继续提供5万美元的支持， 每年为P&F计划提供配套资金。这笔额外的资金将使我们能够提供四个 每年奖金25,000元。我们还计划通过鼓励翻译研究领域的多样化， 研究不同类型干预措施的应用程序（例如，改善人口健康的干预措施）， 研究人群（例如亚裔美国人人群和LGBTQ患者），以及研究人员的专业领域 受资助者（例如环境科学、临床专科和附属专科的广度）。的成功 迄今为止，P&F计划反映了我们中心的跨学科性质和强大的研究基础， 提供.通过更新CCDTR，P&F计划将能够继续提供必要的 为新一代创新和多样化的糖尿病翻译研究人员提供资金支持， 他们在未来获得长期资金的机会。

PROJECT SUMMARY – Pilot and Feasibility Program The Pilot and Feasibility grant program at the Chicago Center for Diabetes Translation Research (CCDTR) supports new areas of inquiry in diabetes-related translation research, with a special focus on vulnerable populations. The main aim of P&F program is to provide funding for investigators to explore novel hypotheses and to obtain preliminary data in order to secure long-term support from conventional funding mechanisms. Funding from the P&F program has supported new investigators who are seeking to become fully independent scientists in diabetes translation research and established investigators who are seeking to initiate diabetes- related research. Since its inception in 2011, the CCDTR P&F program has received 20 applications and has awarded 11 grants. Thus far these pilot grants have led to 15 abstract presentations, 4 peer-reviewed publications, and 10 grant applications submitted, with subsequent funding of 6 grants from the NIDDK, NHBLI, and AHRQ. The P&F program has made a difference for many investigators and has launched the careers of several investigators in the fields of diabetes translational research. Our breadth of funding is demonstrated in the number of institutions and types of interventions funded. About 40% of grantees are from outside the University of Chicago. The grantees' areas of study have included assessments of sleep interventions to improve diabetic outcomes, improving care of patients with pre-end-stage kidney disease, community health worker interventions, mobile phone interventions on sedentary behavior, and outcomes of women with type 2 diabetes and breast cancer. Looking forward, we plan to continue our successful P&F program, which has been an integral part of the CCDTR in fostering collaboration and has led to important research findings, and further expand its scope. We are requesting continuing support at the level of $50,000 per year. The Dean of the Biological Sciences Division, Kenneth Polonsky, MD, will continue his support by providing $50,000 in matching funds per year towards the P&F program. This supplemental funding will allow us to grant four awards of $25,000 per year. We also plan to diversify the areas of translation research funded by encouraging applications that study diverse types of interventions (e.g. interventions to improve population health), the populations studied (e.g. Asian American populations and LGBTQ patients), and the fields of expertise of the grantees (e.g. environmental science, breadth of clinical specialties and subspecialties). The success of our P&F program to date is a reflection of the interdisciplinary nature of our center and the strong research base it provides. Through a renewal of the CCDTR, the P&F program will be able to continue to provide necessary funding support to a new generation of innovative and diverse diabetes translation researchers and increase their chances of securing long-term funding in the future.